PGEN (Precigen Inc) Net Profit

PGEN (Precigen) - company brandmark

The market capitalization trend of Precigen, Inc. (PGEN) reflects the dynamics of a company whose R&D expenses are covered by existing reserves, with the current figure standing at -0.34. The business relies on the UltraVector platform, where PRGN-2012 tests and FDA approvals have become key growth drivers. Synthetic biology enables the programming of genes for oncology therapy, establishing the technological foundation of modern medicine.

PGEN (Precigen, Inc.) Net Profit history from 07/04/2022 to 10/30/2026

Analytical breakdowns and data insights for company Precigen (PGEN)

- price and consensus price forecast:
Stock Quotes Precigen Corp|PGEN - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization Precigen Corp|PGEN - Real Price to Acquire Entire Company
- book capitalization data:
Accounting Value of a Share Precigen|PGEN - Book Capitalization|Market Capitalization to Book Value precigen.com|PGEN - Aggregate Company Assets
- debt and solvency information:
Total Debt to Equity Ratio Precigen, Inc.|PGEN - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Precigen Inc|PGEN - Company Total Debt|Debts to Book Capitalization Precigen Corp|PGEN - Company Long-Term Debt|Company Short-Term Indebtedness Precigen|Immediate Liquidity precigen.com
- net income and valuation multiples indicators:
PGEN - Company Net Income
Summary company analysis:Precigen, Inc.
Core merchandise of Intrexon

Accurate monitoring of net income is critical for minimizing capital risks amid volatility. This metric measures the final operating efficiency of the business, excluding reporting lags. By analyzing the current profit levels of Precigen, Inc. (PGEN) on the GURU.Markets platform, an investor can discern the asset's real financial stability. The trend of this indicator confirms the viability of the diversified gene therapy pipeline of Precigen, Inc. (PGEN), allowing for an assessment of how multi-profile clinical developments impact overall profitability.

Main competitors

Net Income argenx BVBA|BNTX (BioNTech SE) - Net Profit|Net Profit Abivax Pharma|Net Income ADMA (ADMA Biologics, Inc.)|PTGX (Protagonist Therapeutics, Inc.) - Final Profit|Net Profit IMVT (Immunovant Corp)|Net Financial Result Kiniksa Corp (KNSA)|GRFS - Company Net Income|adaptivebiotech.com (ADPT) - Net Income|Celldex Therapeutics, Inc. (CLDX) - Company Net Income|Net Income Aurinia Pharmaceuticals Inc|Net Income BCRX|Net Profit Vera Corp|Company Net Income Dianthus Therapeutics (DNTH)|pharvaris.com - Company Profit|Net Profit ABCL (AbCellera Biologics Inc)|Tourmaline Bio Inc (TRML) - Company Net Income|PHAR - Company Net Income|Profit After Tax NKTR|Upstream Bio Inc (UPB) - Company Net Income|zenasbio.com - Final Profit|IMNM (Immunome) - Net Profit|Company Net Income Gossamer Bio Inc GOSS|Net Profit KALV|Net Income Septerna Pharma SEPN|Net Profit PVLA (Pieris Pharmaceuticals)|Net Financial Result savarapharma.com (SVRA)|Rigel Pharmaceuticals, Inc. - Net Profit|Annual Net Income AnaptysBio Inc (ANAB)|ATXS: Net Profit|Company Net Income enGene Corp (ENGN)|Company Net Income RAPT Therapeutics, Inc.|Company Profit JBIO (Aerovate)|Net Income ACRS (Aclaris Therapeutics, Inc.)|KYTX (Kyverna Therapeutics Inc.) - Final Profit|Net Profit TLSA (Tiziana Life Sciences PLC)|Net Financial Result Cabaletta Bio Inc (CABA)|VTYX - Company Net Income|THTX (theratech.com) - Company Profit|AVTX: Net Profit|Net Income Eledon Pharmaceuticals Inc.|Net Income AGEN|Climb Bio, Inc (CLYM) - Net Financial Result|Company Net Income Zura Bio Limited (ZURA)|ATYR: Profit After Tax|Net Profit ADAG (Adagene Inc.)|Annual Net Income ImageneBio|Shattuck Therapeutics - Net Profit|Company Net Income Equillium, Inc.|connectbiopharm.com (CNTB) - Company Net Income|Company Profit IMUX|Company Net Income Atara Biotherapeutics, Inc.|InflaRx GmbH - Profit After Tax|Net Profit XFOR|ACET (adicetbio.com) - Final Profit|Net Profit CELU (Celularity)|Net Profit inmunebio.com INMB|BRNS - Company Net Income|Final Profit KZR (Kezar Life Sciences Inc.)|SAB Biotherapeutics, Inc (SABS) - Company Net Income|Net Income Akari Therapeutics, Plc|ENLV (Enlivex Therapeutics Ltd) - Net Profit|Net Profit Q32 Bio Corp|Net Income GOVX (GeoVax)|EDSA (Edesa Biotech Inc) - Final Profit|Net Profit IBIO (iBio Corp)|Net Financial Result Carisma Therapeutics Inc (CARM)|XTLB - Company Net Income|Bolt Biotherapeutics (BOLT) - Net Income|hcwbiologics.com (HCWB) - Company Net Income|Net Income Aptevo Therapeutics Inc.|Net Income AIM|Net Profit Aditxt Corp|Company Net Income GRI Bio, Inc. (GRI)|xortx.com - Company Profit|Net Profit HIND (Vyome Holdings)|Revelation Biosciences Inc (REVB) - Company Net Income|INDP - Company Net Income|Profit After Tax SCNI|calcimedica.com (CALI) - Company Net Income|Affimed N.V. - Final Profit|ALLK (Allakos Inc) - Net Profit|Company Net Income HOOKIPA HOOK|Net Profit IGMS|Net Income iTeos Pharma ITOS|Net Profit OCEA (Ocean Biomedical, Inc.)|Net Financial Result tcbiopharm.com (TCBP)|Third Harmonic Bio, Inc. - Net Profit